Phase I/II study of the combination of Oxaliplatin and S-1 in patients with advanced/recurrent colorectal cancer
Ontology highlight
ABSTRACT: Interventions: S-1 is administered orally at the dose of 40mg/m2 twice a day for 21 days, followed by 7-14 days rest. L-OHP is administered intravenously biweekly(day 1 and 15). On 2nd steps L-OHP is administered with RD intravenously biweekly more than 2 courses. The doses of L-OHP are 70mg/m2 for level 1, 85mg/m2 for level 2, and 55mg/m2 for level 0.
Primary outcome(s): Step1:safety;adverse events Step2:Disease control rate
Study Design: Single arm Non-randomized
DISEASE(S): Unresectable Advanced/recurrent Colorectal Cancer
PROVIDER: 2609838 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA